Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II SEC filings (Ticker: SNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SNPX SEC filings page on Stock Titan provides access to the historical regulatory record of Synaptogenix, Inc., which later changed its name to TAO Synergies Inc. and its Nasdaq ticker to TAOX. These documents include current reports, proxy statements, and registration-related materials that show both the company’s biopharmaceutical activities and its subsequent shift to a TAO-focused digital asset treasury strategy.
Among the key filings is a Form 8-K dated June 27, 2025, in which the company reports filing a certificate of amendment to change its name to TAO Synergies Inc. and explains that its common stock would cease trading under the SNPX symbol and begin trading under TAOX on the Nasdaq Capital Market. The filing notes that the CUSIP for the common stock did not change and clarifies that the name change did not alter the rights associated with the shares.
Another Form 8-K dated June 24, 2025 discusses the company’s initial purchase of the TAO token as part of its cryptocurrency treasury strategy and the engagement of BitGo to provide qualified custody, staking, and trading services. This filing describes how the company planned to generate yield by staking TAO from qualified custody and states that the initial acquisition was funded from cash reserves.
A definitive proxy statement on Schedule 14A dated July 7, 2025, filed under the TAO Synergies Inc. name but referencing the former Synaptogenix identity, outlines matters to be voted on at a special meeting of stockholders. These include authorization of share issuances related to Series D preferred stock and warrants, amendments to the company’s equity incentive plan (including renaming it as the TAO Synergies Inc. 2020 Equity Incentive Plan), and potential adjournment of the meeting if additional proxies are needed.
Through Stock Titan, users can view these and other historical SNPX filings and take advantage of AI-powered summaries that highlight the main points of complex documents. The platform surfaces information from current reports, proxy materials, and other SEC submissions so that investors can more quickly understand name changes, financing structures, equity plans, and strategic shifts, and then follow the company’s ongoing disclosures under its current TAOX ticker.
Synaptogenix, Inc. (Nasdaq: SNPX) filed an 8-K on June 24, 2025 disclosing two related developments under Items 7.01 and 8.01.
First, the Company executed its initial purchase of the cryptocurrency “TAO” as the opening step in a previously announced digital-asset treasury strategy. Funding for the acquisition came directly from existing cash on the balance sheet; no external financing or equity issuance was mentioned.
Second, Synaptogenix appointed BitGo Trust Company, Inc. as its qualified custodian and trading partner. BitGo will (1) hold the Company’s TAO in regulated, insured cold storage, (2) facilitate additional TAO purchases via its platforms and OTC desk, and (3) enable TAO to be staked directly from custody. Management states that staking has already begun to generate revenue, positioning the digital-asset holdings as an income-producing treasury component while maintaining security and compliance.
No dollar amounts, number of tokens, staking yields, or risk-management parameters were provided in the filing. A press release containing the same information was furnished as Exhibit 99.1 and is expressly not incorporated by reference into Exchange Act filings.
Key investor takeaways:
- Synaptogenix is now exposed to cryptocurrency price volatility and operational risks.
- The partnership with a regulated custodian and the revenue-generating staking model signal an intent to treat TAO as a strategic, yield-bearing asset rather than a passive holding.
- Absence of quantitative disclosures limits assessment of materiality at this stage.
Synaptogenix has filed Form D for a completed offering of securities under Rule 506(b) of Regulation D. The biotechnology company raised $5.5 million through the sale of equity securities and warrants to 5 investors, with the offering closing on June 23, 2025.
Key details of the offering:
- Sales commissions totaled $385,000, paid to GP Nurmenkari Inc.
- Securities were offered in Illinois, New York, and Ohio
- The offering duration is less than one year
- No minimum investment requirement was specified
Company leadership includes Joshua Silverman as Executive Chairman, Robert Weinstein as CFO, and directors William Singer, Bruce T. Bernstein, and Jonathan L. Schechter. The company is headquartered in New York and was incorporated in Delaware over five years ago.